Is Amwill Health overvalued or undervalued?

As of 24 October 2025, Amwill Health's valuation grade has moved from very attractive to fair. The company appears to be fairly valued at this time. Key ratios include a PE ratio of 9.69, an EV to EBITDA of 8.66, and a ROE of 15.50%.
In comparison to its peers, Amwill Health's PE ratio is significantly lower than that of Sun Pharma, which stands at 35.55, indicating that Amwill Health may be undervalued relative to this competitor. Additionally, Dr. Reddy's Labs, which is rated very attractive, has a PE of 18.88, further emphasizing Amwill's relative valuation position. Notably, while Amwill Health has shown a 1-week stock return of 0.97%, it has underperformed the Sensex over the past month, which returned 3.05%.